1 The median duration between exposure and symptom onset was ap
2 The median duration from implant to erosion was 14 days, but
3 The median duration from implantation to VLST presentation wa
4 The median duration of acyclovir therapy was also significant
5 The median duration of anaesthesia in the general anaesthesia
6 The median duration of antibiotic therapy was 6 weeks, of whi
7 1 were B. afzelii, 1 was B. garinii, and 1 was B. bissettii
The median duration of BL after starting antibiotic treatment
8 The median duration of BL before diagnosis was 27 days (inter
9 Among patients who responded to cladribine therapy,
the median duration of clinical response was 9 months (range,
10 The median duration of DAA therapy was 12 weeks (range, 6-24
11 The median duration of diabetes was 13.0 (interquartile range
12 t initial diagnosis of Stargardt disease was 9.5 years, and
the median duration of disease was 21.5 years.
13 The median duration of disease-free survival was 6.8 years (9
14 cinoma at high risk for tumor recurrence after nephrectomy,
the median duration of disease-free survival was significantl
15 The median duration of drug treatment was 1.48 y (interquarti
16 age of epilepsy onset was 5 years (range, 3-11 years), and
the median duration of epilepsy was 4 years (range, 1-10 year
17 The median duration of experience (10 years) was used as the
18 The median duration of follow-up for overall survival and saf
19 The median duration of follow-up was 13.0 months (IQR 7.6-14.
20 The median duration of follow-up was 13.2 (IQR, 7.4-17.7) yea
21 The median duration of follow-up was 15.3 months.
22 The median duration of follow-up was 2.2 years.
23 The median duration of follow-up was 59 months.
24 The median duration of follow-up was approximately 30 months.
25 The median duration of follow-up, including the current exten
26 The median duration of intervals of posturing was 3.0 hours (
27 The median duration of ITP before being recognized as multire
28 The median duration of observation was 3.6 years.
29 The median duration of oral mexiletine therapy was 36 months,
30 The median duration of oxygen therapy was 11.6 hours, and the
31 patients with platinum-sensitive, recurrent ovarian cancer,
the median duration of progression-free survival was signific
32 The median duration of response was 14.5 months (95% CI 9.4 t
33 The median duration of response was 19.1 weeks.
34 The median duration of response was 20 weeks (range, 6-103 we
35 The median duration of response was 7.6 months (95% confidenc
36 The median duration of response was not reached (95% CI, 12.1
37 to response was 17.9 weeks (range, 7.3 to 32.4 weeks), and
the median duration of response was not yet reached (range, 1
38 th BRAF(V600)-mutant melanoma without brain metastases, but
the median duration of response was relatively short.
39 The median duration of TDF exposure was 54 months, and the to
40 The median duration of telemedicine evaluation was 20 minutes
41 was identified to have a significant, consistent effect on
the median duration of therapy of laBCC and mBCC.
42 The median duration of therapy was 2.79, 0.4, and 1.63 years,
43 The median duration of treatment for the 204 patients was 5.7
44 The median duration of treatment was 13.8 months.
45 Among 1,202 ICU patients with bacteremia,
the median duration of treatment was 14 days, but with wide v
46 The median duration of treatment was 21 months.
47 The median duration of treatment was significantly shorter wi
48 The median duration of visits increased from 133 minutes (int
49 The median durations of hospitalization and in-hospital proph
50 uppression, typically only 1 to 2 agents were required, and
the median durations of systemic pharmacologic immunosuppress